2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.71

PP01.71 - Jia Zhong

Pdf Summary

This study analyzes the effectiveness of various treatment strategies for patients experiencing transformation from non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations to small-cell lung cancer (SCLC). The research is retrospective, focusing on patients with SCLC transformation, a condition increasingly observed among EGFR-mutant NSCLC patients, yet lacking extensive treatment studies.<br /><br />The study includes 62 patients, where 50 had EGFR mutations. Statistical methods, including Kaplan-Meier curves, were utilized to compare progression-free survival (PFS) and overall survival (OS) among different treatment regimens.<br /><br />The key findings highlight that EGFR-mutant patients show a better response to first-line treatment strategies that combine EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy (referred to as TKIsC), exhibiting superior median PFS. For second-line and subsequent treatments, a chemotherapy regimen based on taxanes was revealed to be the most effective. Specifically, patients undergoing the taxanes-based chemotherapy showed a median PFS of 5.96 months, outperforming camptothecin-based and other chemotherapy regimens.<br /><br />The demographic data indicate that the majority of the EGFR-mutant group were never-smokers (76%) and predominantly female (64%), whereas the EGFR wild type group comprised entirely of males, with a higher smoking history (75%).<br /><br />The study emphasizes the importance of tailored treatment strategies in managing SCLC transformation in EGFR-mutant NSCLC patients, suggesting that combining TKIs with chemotherapy offers substantial benefits in the first treatment line and taxane-based regimens provide superior efficacy in later stages. This research provides valuable insights into improving prognostic outcomes for this patient subset, addressing an area with previous limited data.

Keywords

NSCLC

SCLC transformation

EGFR mutations

treatment strategies

Kaplan-Meier curves

progression-free survival

overall survival

TKIsC

taxanes-based chemotherapy

demographic data